|Bid||521.99 x 1100|
|Ask||530.00 x 800|
|Day's Range||516.25 - 527.33|
|52 Week Range||324.80 - 539.30|
|PE Ratio (TTM)||77.41|
|Earnings Date||Oct 17, 2018 - Oct 22, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||564.47|
NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.
Jim Cramer said on CNBC's "Mad Money Lightning Round" that he spoke to Magna International Inc. (USA) (NYSE: MGA ) and it didn't leave him warm and fuzzy about the group. He wants to be careful ...
CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.
A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.
TransEnterix (NYSE: TRXC) is seeing its revenue climb on more sales following its initial U.S. Food and Drug Administration clearance late last year, although the company is still showing losses overall. On Tuesday, the Research Triangle Park-based surgical robot maker reported revenue of $6.4 million in the second quarter of 2018, compared to revenue of just $1.6 million in the second quarter of last year. TransEnterix reported a net loss of $34.2 million, or $0.17 per share, for the second quarter of 2018, compared to a net loss of $14.7 million, or $0.11 per share, for the second quarter of last year.
Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.
DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.